CDMO Nucleus RadioPharma's Expansion Plans Raise Concerns—Radioactive Drug Production Capacity to Double

CDMO Nucleus RadioPharma, two years after completing its first round of funding, is pursuing an aggressive expansion strategy into two key regions that it believes will "significantly optimize" market access in the promising field of cancer treatment.

According to an official announcement from Nucleus on October 21, the plan to upgrade the facilities in Mesa, Arizona, and Springhouse, Pennsylvania, aims to integrate the research, development, and commercial production capabilities of each site into a "unified platform" to maximize efficiency. A company spokesperson further pointed out that the project is expected to double Nucleus's overall production capacity, that is, to double its original capacity.

Specifically, the Arizona facility covers 53,000 square feet, while the Pennsylvania facility north of Philadelphia has 48,000 square feet of expansive space. With the completion of the expansion project expected by the end of 2026, Nucleus expects to create about 50 new jobs in each of the two locations, injecting new vitality into the local economy.

Of particular concern, Nucleus stressed that the upgrade will greatly promote the widespread use of radiopharma, which is particularly valuable due to its limited shelf life. Charles Conroy, CEO of Nucleus RadioPharma, elaborated in the official statement: "To maximize the potential to treat the millions of patients facing limited options, therapeutic radiopharma must be accessible, in the areas where patients need it most urgently." "Our expansion plans will significantly improve patient access to these life-saving treatments, accelerate the clinical trial process, and potentially reduce time to market for new therapies by 30 percent," he added.

In addition to the existing facility at the Mayo Clinic in Rochester, Minnesota, Nucleus revealed that the expanded facility will bring radiopharmaceutical manufacturing capacity within a four-hour drive of 60% of the U.S. population. The Arizona facility will serve patients from the Asian region, while the Pennsylvania facility will accommodate patients from Europe.

Robert Uzzo, CEO of Fox Chase Cancer Center, said the expansion of manufacturing capacity and clinical trial sites achieved by Nucleus will fundamentally improve "outcomes for patients battling cancer." Fox Chase Cancer Center and Mayo Clinic, as key partners of Nucleus, have high hopes for this expansion.

Back in 2022, the official launch of the nuclear program was designed to improve access to radiopharmaceuticals; It is backed by a number of financial backers, including Astrazeneca and GE Healthcare.